Lexaria Bioscience (NASDAQ:LEXX) Stock, Quote.Headers.trade-ideas

Lexaria Bioscience

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Movers

News

Pre-Market Outlook

Markets

Trading Ideas

ALBT

ANNX

BARK

CAPT

Core Scientific, Inc. - Class A Common Stock

CORZ

FGEN

LEXX

MBOT

MLGO

NIVF

PLTN

SQNS

WIMI

YGMZ

Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

ACAD

AEVA

ASAN

ASRT

BCAN

BLDE

The Beachbody Company, Inc. Class A Common Stock

BODI

BWMN

CLRO

CRBU

CTMX

DTSS

ENPH

ESGL

FNCH

GERN

GOEV

HRTG

IONM

JANX

JFBR

KITT

LGCL

LICY

MNSO

NRXP

NUKK

OCUL

ONON

ORCL

PACK

PRST

RERE

RGLS

RNLX

SGLY

SMXT

SPPL

TALK

VINC

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering.

Why Lexaria Bioscience (LEXX) Shares Are Moving

Lexaria Bioscience Corp

Global Engine Group Announces Pricing Of $8M Initial Public Offering At Public Offering Price Of $4.00 Per Share

Across the recent three months, 4 analysts have shared their insights on Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $45.0, a high estimate of $45.00, and a low estimate of $45.00. Marking an increase of 6.31%, the current average surpasses the previous average price target of $42.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833694_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Essential Utilities's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Fowler</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Jonathan Reeder</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Essential Utilities. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Essential Utilities compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Essential Utilities's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Essential Utilities's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WTRG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Essential Utilities analyst ratings.</a>
<h2>Unveiling the Story Behind Essential Utilities</h2>
Essential Utilities is a Pennsylvania-based holding company for us water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Nearly three fourths of its water earnings come from Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. Essential exited its noncore competitive water and energy services businesses.
<h3>Essential Utilities: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Essential Utilities's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -0.53%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.
Net Margin: Essential Utilities's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Essential Utilities's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Essential Utilities's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.44%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Essential Utilities's debt-to-equity ratio is below the industry average at 1.17, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

WTRG

4 Analysts Have This To Say About Essential Utilities

Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $257.67, with a high estimate of $282.00 and a low estimate of $215.00. Marking an increase of 5.65%, the current average surpasses the previous average price target of $243.89. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833681_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Labcorp Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$261.00</td>
<td>$258.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Labcorp Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Labcorp Holdings</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 6.17% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Labcorp Holdings's ROA excels beyond industry benchmarks, reaching 1.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Analyst Ratings For Labcorp Holdings

Analysts' ratings for Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $117.0, a high estimate of $135.00, and a low estimate of $103.00. This upward trend is apparent, with the current average reflecting a 13.15% increase from the previous average price target of $103.40.
<img src="https://www.benzinga.com/files/images/story/2024/1726833658_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Advanced Energy Indus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$128.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Krish Sankar</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$103.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Advanced Energy Indus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Advanced Energy Indus compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Advanced Energy Indus's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Advanced Energy Indus's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AEIS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Advanced Energy Indus analyst ratings.</a>
<h2>Get to Know Advanced Energy Indus Better</h2>
Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in the United States, with the rest primarily from Asia and Europe.
<h3>Advanced Energy Indus: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Advanced Energy Indus's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -12.17%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Advanced Energy Indus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.12% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Advanced Energy Indus's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Advanced Energy Indus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.59%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.88, Advanced Energy Indus faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEIS

Analyst Expectations For Advanced Energy Indus's Future

In the last three months, 4 analysts have published ratings on Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.25, a high estimate of $48.00, and a low estimate of $38.00. Surpassing the previous average price target of $37.00, the current average has increased by 14.19%.
<img src="https://www.benzinga.com/files/images/story/2024/1726833647_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Amkor Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Peter Peng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$48.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amkor Tech. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amkor Tech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amkor Tech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amkor Tech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amkor Tech analyst ratings.</a>
<h2>Discovering Amkor Tech: A Closer Look</h2>
Amkor Technology Inc is a provider of outsourced semiconductor packaging and test services to integrated device manufacturers, fabless semiconductor companies, and contract foundries. The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
<h3>Financial Milestones: Amkor Tech's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Amkor Tech showcased positive performance, achieving a revenue growth rate of 0.24% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Amkor Tech's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 4.58%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Amkor Tech's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.66%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Amkor Tech's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.99%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Amkor Tech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKR

4 Analysts Assess Amkor Tech: What You Need To Know

During the last three months, 13 analysts shared their evaluations of IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $265.92, a high estimate of $300.00, and a low estimate of $230.00. Marking an increase of 2.28%, the current average surpasses the previous average price target of $260.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833637_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of IQVIA Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$256.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$288.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$242.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$251.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of IQVIA Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for IQVIA Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into IQVIA Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IQV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IQVIA Hldgs analyst ratings.</a>
<h2>Discovering IQVIA Hldgs: A Closer Look</h2>
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
<h3>Financial Insights: IQVIA Hldgs</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, IQVIA Hldgs showcased positive performance, achieving a revenue growth rate of 2.31% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): IQVIA Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 5.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): IQVIA Hldgs's ROA excels beyond industry benchmarks, reaching 1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: IQVIA Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.0, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 13 Analyst Recommendations For IQVIA Hldgs

Goldman Sachs analyst Jerry Revich maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Neutral and lowers the price target from $72 to $62.

Price Target

Goldman Sachs Maintains Neutral on Terex, Lowers Price Target to $62

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $218.3, with a high estimate of $250.00 and a low estimate of $190.00. Observing a downward trend, the current average is 13.6% lower than the prior average price target of $252.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833616_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Charles River by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$203.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$191.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$239.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$230.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Charles River. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Charles River's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles River analyst ratings.</a>
<h2>Get to Know Charles River Better</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Charles River's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -3.19%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Charles River's net margin excels beyond industry benchmarks, reaching 8.77%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Charles River's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.12%, the company showcases effective utilization of assets.
Debt Management: Charles River's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Charles River In The Eyes Of 10 Experts

The Federal Reserve announced Wednesday<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead"> a deep 50 basis-point cut to its Fed funds rate, </a>which is likely to ease the pressure on consumers. An analyst, however, sees a return of recession along with stagnation.
What Happened: &#8220;Get ready for stagnation,&#8221; said GLJ Research&#8217;s Gordon Johnson, adding that, this is the &#8220;inflation is Transitory&#8221; mistake all over again. To make his case, he noted four corporate announcements suggesting the near could be challenging.
China Drags Skechers: Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), which designs, manufactures and distributes footwear, sees softness in China&#8217;s business. CFO John Vandemore said, at the Wells Fargo Consumer Conference, &#8220;We've definitely seen worse conditions unfold in China than we expected for the back half of the year, so I would expect the back of the year's going to be more disappointing than what we had originally thought.&#8221; The shares reacted with a sharp tumble on Thursday, settling down 9.62% to $61.56
Rough Road For Mercedes-Benz: Also German automaker Mercedes-Benz Group AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGAF#OTC">MBGAF</a>) late Thursday said its 2024 earnings before interest and taxes will likely come in &#8220;significantly below&#8221; the previous year, citing a further deterioration in the macroeconomic environment, mainly in China. The automaker also said it expects its adjusted return on sales to be between 7.5% and 8.5%, down from its earlier forecast of 10% to 11%. The company&#8217;s shares listed on the Frankfurt exchange fell nearly 7%.
See Also: <a href="https://www.benzinga.com/money/best-depression-stocks">Best Depression Stocks</a>
FedEx Doesn&#8217;t Deliver: Package-shipping company FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) reported first-quarter earnings that fell year-over-year and missed expectations. The company reduced the high end of the full-year adjusted operating income guidance. The predicament was blamed on circumspect consumers favoring cheaper services over pricey and speedier options. The stock fell over 13% in premarket trading on Friday.
Lennar&#8217;s Underwhelming Quarter: Homebuilder Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported roughly 8% revenue growth to $9.42 billion and earnings per share were up 10% but the average sales price of houses fell.
More Cuts At Warner Music: Entertainment and record-label company Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) said Thursday it plans to reduce its workforce by about 750 employees, representing 13% of its total headcount, more than the 10% expected earlier.
R-Word Still Floats Around: Chief Global Strategist of BCA Research Peter Berezin said in an X post that the 50 basis-point cut and another 50 bps reduction the central bank is penciling in before the year-end <a href="https://www.benzinga.com/news/earnings/24/09/40954521/wall-street-looks-to-pause-after-s-ps-record-performance-as-fed-rate-cut-euphoria-fades-and-hard-la">may not ensure a soft landing. </a>He pointed out to the previous two rate-cut cycles when recession followed following 100 basis-point cuts.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the S&amp;P 500 Index, fell 0.26% to $567.76, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data. </a>The ETF, however, is up nearly 21% so far this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40948046/fedex-q1-earnings-revenue-miss-eps-miss-lowered-guidance-challenging-quarter">FedEx Q1 Earnings: Revenue Miss, EPS Miss, Lowered Guidance — &#8216;Challenging Quarter&#8217;</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Earnings

Equities

Economics

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

MBGAF

Brace For Stagflation After Fed's Benevolence, Warns Analyst, Raising 5 Corporate Red Flags: 'Inflation Is Transitory Mistake All Over Again'

Evercore ISI Group analyst Greg Melich maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Outperform and lowers the price target from $3900 to $3350.

Evercore ISI Group Maintains Outperform on AutoZone, Lowers Price Target to $3350

As of Sept. 20, 2024, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Brooge Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BROG#NASDAQ">BROG</a>)</h3>
<ul>
<li>On June 5, Brooge Energy announced the receipt of Nasdaq non-compliance letter. The company's stock gained around 82% over the past month and has a <a href="https://www.benzinga.com/quote/BROG">52-week high of $6.66</a>.</li>
<li>RSI Value: 83.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>BROG Price Action: Shares of Brooge Energy gained 14.9% to close at $1.77 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Battalion Oil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BATL#NYSE">BATL</a>)</h3>
<ul>
<li>On Sept. 19, Battalion Oil announced it has amended its merger agreement with Fury Resources for the acquisition of all outstanding shares of Battalion at $7.00 per share in cash. Avi Mirman, Co-Founder and Chairman of Fury Resources stated "With this acquisition, Fury has secured a foothold in one of the world&#8217;s most prolific basins. Our team has significant experience in the region, and we believe these assets present a compelling value proposition for our investors. With a deep inventory of high return locations and consolidation opportunities in the area, we believe this asset can be scaled quickly and provide a meaningful return to our investors. We have strong institutional support for this transaction, including the Rollover Stockholders. We view their decision to stay in the investment opportunity as a strong vote of confidence in our ability to deliver results and are excited for us to get to work." The company's stock gained around 17% over the past month and <a href="https://www.benzinga.com/quote/BATL">has a 52-week high</a> of $9.69.</li>
<li>RSI Value: 83.48</li>
<li>BATL Price Action: Shares of Battalion Oil fell 3.6% to close at $2.94 on Thursday. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40952252/nvidia-tesla-rally-as-dow-s-p-500-surge-to-fresh-highs-after-fed-cuts-rates-fear-index-remains-in-g">Nvidia, Tesla Rally As Dow, S&amp;P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Short Ideas

BATL

BROG

Top 2 Energy Stocks That May Collapse In Q3

The Federal Reserve surprised investors earlier this week by enacting an aggressive 50 basis point cut in benchmark interest rates, marking the first such move since March 2020.
What happened: The dip in borrowing costs immediately boosted risky asset classes like cryptocurrencies, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) spiking 7.7% since the announcement.
The rate was <a href="https://www.federalreserve.gov/newsevents/pressreleases/monetary20200315b.htm">last slashed in an emergency meeting</a> on March 15, 2020, in reaction to the risk posed by the COVID-19 pandemic to the U.S. economy. The federal funds rate was lowered to the range of 0%-0.25%.
At that time, one Bitcoin was priced at $5,392.31. Accordingly, an investment of $1,000 would have fetched you 0.1854 units of the world's largest cryptocurrency. 
Today, the price of one Bitcoin has ballooned to $63,797.59, meaning that 0.1854 BTCs would be worth $11,831.21, marking a whopping 1083% return.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40950912/bitcoins-reserve-asset-appeal-increased-due-to-state-of-us-federal-deficit-and-debt-says-b">Bitcoin&#8217;s Reserve Asset Appeal Increased Due To State Of US Federal Deficit And Debt, Says BlackRock: A Hedge Against &#8216;Possible Future Events&#8217; Affecting The Dollar</a>
Why It Matters: Bitcoin, along with the broader cryptocurrency market, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40945629/bitcoin-could-surge-after-interest-rate-cut-as-macro-drivers-take-over-standard-chartered">was expected to witness substantial upsides</a> following the bold reduction in interest rates, according to British multinational bank Standard Chartered.
Other noted macro analysts like Alex Kruger have also issued bullish forecasts for the leading cryptocurrency, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942948/what-does-the-feds-interest-rate-cut-mean-for-bitcoin-50-bps-cut-is-the-sweet-spot-says-ma">calling the 50-basis point cut a "sweet spot.</a>"
Price Action: At the time of writing, Bitcoin was exchanging hands at $63,731.27, up 2.83% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40951267/max-keiser-attacks-michael-saylor-for-finding-fault-with-el-salvadors-bitcoin-strategy-you">Max Keiser Attacks Michael Saylor For Finding Fault With El Salvador&#8217;s Bitcoin Strategy: &#8216;You Owe Nayib Bukele An Apology&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

If You Invested $1000 in Bitcoin When The Fed Last Cut Interest Rates, Here's How Much It'd Be Worth Today

B of A Securities analyst Ross Fowler reinstates American Water Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) with a Underperform and announces $140 price target.

Initiation

B of A Securities Reinstates Underperform on American Water Works, Announces $140 Price Target

A new analysis suggests that Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) correction phase may have come to an end, with experts now predicting a potential <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40926729/bitcoin-spikes-above-61-000-as-fed-implements-50-bps-rate-cut">surge towards the $70,000 mark</a>.
What Happened: According to a 10x Research report, trading signals have increased long positions to 70% net long for the first time, indicating a favorable buying opportunity for both Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) with a 2-3 month horizon.
The report highlights that weekly reversal indicators are showing signs of bottoming out for the first time since the correction began in March, signaling a more positive outlook for the leading cryptocurrency.
Bitcoin&#8217;s weekly Relative Strength Index (RSI) is attempting to establish a medium-term low at 50%, further supporting the bullish sentiment. Key support levels are identified at $52,599 and $56,000, with resistance at $64,490. 
Analysts suggest that a break above the August short-term high of $64,490 could propel Bitcoin toward $70,000 or beyond.
The recent <a href="https://www.benzinga.com/markets/asia/24/09/40951221/bank-of-japan-leaves-interest-rate-at-0-25-diverging-from-feds-50-basis-point-cut">50 basis point rate cut</a> by the Federal Reserve has added an interesting dynamic to the market.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40945847/donald-trump-now-trails-kamala-harris-by-4-points-after-9-point-election-odds-turnaround-i">Donald Trump Now Trails Kamala Harris By 4 Points After 9-Point Election Odds Turnaround In Only 9 Days</a>
While historically, such cuts have led to short-term rallies in Bitcoin, lasting 1-2 weeks, the long-term impact remains to be seen. 
Fed Chair Powell&#8217;s cautious framing of the rate cut has left room for interpretation regarding the broader economic outlook.
Interestingly, funding rates for Bitcoin and Ether have returned to double digits, indicating significant bets from futures traders. 
This renewed momentum is primarily driven by activity in the futures market, with rising trading volumes in Korea suggesting increased participation from retail investors.
What&#8217;s Next: As the cryptocurrency market enters the historically bullish fourth quarter, many eyes will be on Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40945629/bitcoin-could-surge-after-interest-rate-cut-as-macro-drivers-take-over-standard-chartered">Bitcoin Could Surge After Interest Rate Cut As Macro Drivers Take Over: Standard Chartered</a></li>
</ul>

$ETH

Bitcoin's Correction Ends, But It Has To Break This Target To Surge To $70K: 10x Research

B of A Securities analyst Ross Fowler reinstates Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) with a Buy and announces $45 price target.

B of A Securities Reinstates Buy on Essential Utilities, Announces $45 Price Target

WIIM

AEMD

Aethlon Medical shares are trading higher after the company announced that it received granted ethics committee approval for Hemopurifier cancer treatment. Also, the European Commission recommended extending the indication of the smallpox and mpox vaccine to adolescents.

B of A Securities analyst Ross Fowler initiates coverage on SJW Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NYSE">SJW</a>) with a Neutral rating and announces Price Target of $65.

B of A Securities Initiates Coverage On SJW Gr with Neutral Rating, Announces Price Target of $65

Biotech

Large Cap

Health Care

General

REGN

The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending The Expanded Approval Of Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) For Eosinophilic Esophagitis In Children Down To 1 Year Of Age

Arq shares are trading lower after the company announced a proposed public offering of common stock, details not disclosed.

GNFT

GENFIT shares are trading higher. The company reported H1 financial results.

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience Corp. announces promising results from a study evaluating its DehydraTECH tech...

Lexaria's DehydraTECH Shows Promise in GLP-1 Drug Study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience reports promising interim results from their diabetes animal study, showcasing...

Lexaria Bioscience Excels in Diabetes Control Study

Lexaria Bioscience (LEXX) has released an update. In a groundbreaking animal study, Lexaria Bioscience has reported that its DehydraTECH-liraglutid...

Lexaria's Innovative Formulation Leads in Weight Loss Study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has announced preliminary findings from its second human pilot study, indicati...

Lexaria's Study Suggests Improved Drug Absorption With Food

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience's second human pilot study shows its DehydraTECH-processed Rybelsus capsules a...

Lexaria Advances Drug Tolerability in Latest Study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience Corp. has announced a partnership with PharmaCO to test its DehydraTECH techno...

Lexaria Bioscience Advances Drug Delivery with PharmaCO Partnership

Lexaria appoints Richard Christopher as CEO

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience Corp., a pioneer in drug delivery platforms, is undergoing a significant trans...

Lexaria Bioscience Ushers in New Leadership and Focus

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience Corp. announces the appointment of Richard Christopher as the new CEO, with ou...

Lexaria Bioscience Appoints New CEO for Growth Era

Lexaria Bioscience (LEXX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okune...

Lexaria Bioscience: Advancing Drug Delivery with DehydraTECH and Strategic Leadership Shift

Press Releases

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

Management

Lexaria Preparing For Strategic Growth

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Positive Results from Lexaria's Molecular Characterization Study

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

First Results from Lexaria's Second GLP-1 Human Pilot Study

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Lexaria Bioscience

Lexaria Bioscience (LEXX) Forecast

Lexaria Bioscience (NASDAQ:LEXX) Stock, Quote.Headers.trade-ideas